The White House’s plans to make significant cuts to funding from NIH is expected to have significant impact on the pharma industry for years to come. Justin Kozak, an executive VP at Founder Shield, ...

Leerink Partnrs has cut its Q3 2025 earnings estimate for Regeneron Pharmaceuticals, citing lowered expectations across the ...